Promis Dx has specialized in developing cancer diagnostic assays using DNA methylation biomarkers. The company developed colorectal cancer, bladder and lung cancer marker. We have evaluated several CRC, Bladder cancer and lung cancer markers in our pilot study. EarlyTect® BC is a diagnostic test for bladder cancer that utilizes urine specimen to detect and monitor the disease in patients. We, Promis Dx, received FDA breakthrough designation for urine-based bladder cacner diagnosis product.
Additional Info
Countries of Interest
United States